Mechanisms mediating the cardioprotective effects of rapamycin in ischaemia-reperfusion injury

Clinical and Experimental Pharmacology and Physiology

Volumn 38, Issue 1, 2011, Pages 77-83

  Liu, You Bin ^a   Yu, Bo ^a   Li, Shu Feng ^a   Fan, Ying ^a   Han, Wei ^a   Yu, Jiang Bo ^a   Wang, Zheng ^a   Li, Xiang Lu ^a   Sun, Li Ping ^a   Yang, Shu Sen ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Cardioprotection; Ischaemia reperfusion injury; Mechanism; Rapamycin

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CREATINE KINASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; LACTATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; HEART INFARCTION SIZE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE FUNCTION; ISOLATED HEART; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT; REPERFUSION INJURY;

ALGORITHMS; ANIMALS; CARDIOTONIC AGENTS; CREATINE KINASE; DRUG EVALUATION, PRECLINICAL; HEMODYNAMICS; L-LACTATE DEHYDROGENASE; MALE; MYOCARDIAL INFARCTION; ORGAN SIZE; RANDOM ALLOCATION; RATS; RATS, WISTAR; REPERFUSION INJURY; SIGNAL TRANSDUCTION; SIROLIMUS;

EID: 78650651690     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2010.05467.x     Document Type: Article

References (27)

1. Derek M, Yellon DS, Derek JH. Myocardial reperfusion injury. N. Engl. J. Med. 2007; 357: 1121-35.
2. Staat P, Rioufol G, Piot C et al. Postconditioning the human heart. Circulation 2005; 112: 2143-8.
3. Laskey WK. Brief repetitive balloon occlusions enhance reperfusion during percutaneous coronary intervention for acute myocardial infarction: A pilot study. Catheter Cardiovasc. Interv. 2005; 65: 361-7.
4. Ma X, Zhang X, Li C, Luo M. Effect of postconditioning on coronary blood flow velocity and endothelial function and LV recovery after myocardial infarction. J. Interv. Cardiol. 2006; 19: 367-75.
5. ATP channels. Circ. Res. 1999; 84: 846-51.
6. Goto M, Liu Y, Yang XM, Ardell JL, Cohen MV, Downey JM. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ. Res. 1995; 77: 611-21.
7. 1 adenosine receptors in rabbit heart. Circulation 1991; 84: 350-6.
8. Khan S, Salloum F, Das A, Xi L, Vetrovec GW, Kukreja RC. Rapamycin confers preconditioning-like protection against ischemia-reperfusion injury in isolated mouse heart and cardiomyocytes. J. Mol. Cell. Cardiol. 2006; 41: 256-64.
9. Xi L, Hess ML, Kukreja RC. Ischemic preconditioning in isolated perfused mouse heart: Reduction in infarct size without improvement of postischemic ventricular function. Mol. Cell. Biochem. 1998; 186: 69-77.
10. Fishbein MC, Maclean D, Moroko PR. The histopathologic evolution of myocardial infarction. Chest 1978; 73: 843-9.
11. Kant R, Diwan V, Jaggi AS, Singh N, Singh D. Remote renal preconditioning-induced cardioprotection: A key role of hypoxia inducible factor-prolyl 4-hydroxylases. Mol. Cell. Biochem. 2008; 312: 25-31.
12. King J. Routine method for the estimation of lactic dehydrogenase activity. J. Med. Lab. Tech. 1959; 16: 265-72.
13. Hughes B. Studies on the starch gel electrophoresis of some human muscle proteins. Clin. Chim. Acta 1961; 7: 597-603.
14. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000; 103: 253-62.
15. Lochner A, Genade S, Moolman JA. Ischemic preconditioning: Infarct size is a more reliable endpoint than functional recovery. Basic Res. Cardiol. 2003; 98: 337-46.
16. Nayler WG, Gordon M, Stephens DJ, Sturrack WJ. The protective effect of prazosin on the ischaemic and reperfused myocardium. J. Mol. Cell. Cardiol. 1985; 17: 685-99.
17. Cumming DV, Heads RJ, Coffin RS, Yellon DM, Latchman DS. Pharmacological preconditioning of primary rat cardiac myocytes by FK506. Basic Res. Cardiol. 1996; 91: 367-73.
18. Sharkey J, Butcher SP. Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischaemia. Nature 1994; 371: 336-9.
19. Dhar DK, Nagasue N, Uchida M et al. Effective prevention of ischemic injury of the dearterialized canine liver by FK506 pretreatment. Transplantation 1993; 56: 1555-8.
20. Edinger AL, Thompson CB. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol. Biol. Cell 2002; 13: 2276-88.
21. Kis A, Yellon DM, Baxter GF. Second window of protection following myocardial preconditioning: An essential role for PI3 kinase and p70S6 kinase. J. Mol. Cell. Cardiol. 2003; 35: 1063-71.
22. Jonassen AK, Sack MN, Mjos OD, Yellon DM. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ. Res. 2001; 89: 1191-8.
23. Hausenloy DJ, Mocanu MM, Yellon DM. Cross-talk between the survival kinases during early reperfusion: Its contribution to ischemic preconditioning. Cardiovasc. Res. 2004; 63: 305-12.
24. Shi Y, Yan H, Frost P, Gera J, Lichtenstein A. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol. Cancer Ther. 2005; 4: 1533-40.
25. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: Targeting the reperfusion injury salvage kinase (RISK)-pathway. Cardiovasc. Res. 2004; 61: 448-60.
26. + channels in rat hearts. Am. J. Physiol. Heart Circ. Physiol. 2006; 290: H1808-17.
27. Li SY, Fang CX, Aberle NS, Ren BH, Ceylan-Isik AF, Ren J. Inhibition of PI-3 kinase/Akt/mTOR, but not calcineurin signaling, reverses insulin-like growth factor I-induced protection against glucose toxicity in cardiomyocyte contractile function. J. Endocrinol. 2005; 186: 491-503.